- Home
- XOS vs JSPR Comparison
XOS vs JSPR Comparison
Compare XOS & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XOS | JSPR |
|---|---|---|
| Founded | 2016 | 2018 |
| Country | United States | United States |
| Employees | 101 | 22 |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.4M | 23.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | XOS | JSPR |
|---|---|---|
| Price | $1.85 | $0.98 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 11 |
| Target Price | $7.00 | ★ $15.50 |
| AVG Volume (30 Days) | 18.8K | ★ 533.6K |
| Earning Date | 05-13-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $29.02 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.60 | $0.62 |
| 52 Week High | $5.60 | $7.19 |
Technical Indicators
Market Signals| Indicator | XOS | JSPR |
|---|---|---|
| Relative Strength Index (RSI) | 57.57 | 50.52 |
| Support Level | $1.74 | $0.81 |
| Resistance Level | $1.89 | $1.12 |
| Average True Range (ATR) | 0.09 | 0.10 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 95.50 | 53.11 |
Price Performance
Historical ComparisonAbout XOS Xos Inc.
Xos Inc is a fleet electrification solutions provider committed to the decarbonization of commercial transportation. Xos designs and manufactures Class 5 through 8 battery-electric commercial vehicles that travel on last-mile, back-to-base routes of up to 200 miles per day. Xos also offers charging infrastructure products and services through Xos Energy Solutions to support electric vehicle fleets. Its products include Stepvan, MDXT, HDXT, Xosphere, and Xos Energy Solutions.
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.